Understanding Prolaris test results June 17, 2022 After a prostate cancer diagnosis, choosing an appropriate treatment path can be incredibly stressful for you and your loved ones. Further complicating the pro... Continue Reading
What is the Prolaris test? June 10, 2022 The Prolaris test is a genetic test for untreated men with prostate cancer that can determine how quickly cancer is growing. Prolaris helps provide clarity abo... Continue Reading
The Next Wave of the Pandemic May 18, 2022 When the Covid-19 pandemic first hit, many patients took what they thought would be a temporary break from preventive care visits to the doctor. However, mor... Continue Reading
New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer May 17, 2022 By Thomas Slavin, M.D., chief medical officer, Myriad Genetics According to the American Cancer Society, in 2022 more than 268,000 men in the United S... Continue Reading
Making Genetic Testing More Inclusive May 12, 2022 Myriad Genetics’ innovative approach to genetic testing gives more women the information they need to stay healthy. By FastCo Works For the past 30 yea... Continue Reading
The Future of Genetic Testing: How a Love of DNA Led to More Comprehensive Tests April 23, 2022 For more than 30 years now, scientists at Myriad Genetics have been finding creative ways to coax new information out of human genes. The love for exploring th... Continue Reading
April 14, 2022 Dear Stakeholders, In 2021, during the most difficult operating environment any of us has ever seen, Myriad Genetics executed a bold transformatio... Continue Reading
Genetic insights for more actionable and personalized prostate cancer March 25, 2022 Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and th... Continue Reading
During Women’s History Month, We’re Celebrating Women’s Contributions at Myriad Genetics March 22, 2022 Throughout March we’re celebrating Women’s History Month, a recognition of the countless contributions women have made here in the U.S. and around the worl... Continue Reading
New Enhancements to Noninvasive Prenatal Screening (NIPS) March 21, 2022 Myriad Genetics was honored to participate in one of the most important conferences for Maternal Fetal Medicine specialists and other medical providers focused... Continue Reading
Inside One of the World’s Most Innovative Companies March 8, 2022 In March 2022, Myriad Genetics was named one of the World’s Most Innovative Companies by Fast Company. Since 2008, Fast Company’s Most Innovative Comp... Continue Reading
Innovating Together: Dr. Alan Stolier and Nicole Lambert March 8, 2022 “Clinicians play a pivotal role in the process of innovation” Dr. Alan Stolier “He’s been a cutting-edge partner and innovator for y... Continue Reading
Myriad Genetics achieves HITRUST certified status for GeneSight February 22, 2022 Information security and privacy is a critical part of the healthcare landscape for clinicians, patients, insurance companies, third party labs and beyond as t... Continue Reading
The impact of prenatal screening on parents and pregnancies February 5, 2022 There are many factors to consider when developing a genetic test or screen. Some common examples include sensitivity, specificity, cost, and turnaround time. T... Continue Reading
The Year Ahead: Innovating and Growing in 2022 and Beyond January 25, 2022 Eighteen months ago, we launched a bold transformation and growth plan for Myriad Genetics. The plan involved change in virtually every part of our business. On... Continue Reading